Erratum to: Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma
BMC Cancer volume 16, Article number: 272 (2016)
Following publication of this work  the authors noticed a mistake within the article’s competing interests section. The correct competing interests section is provided below.
Okuma Y, Hosomi Y, Miyamoto S, Shibuya M, Okamura T, Hishima T. Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma. BMC Cancer. 2016;16:156. doi:10.1186/s12885-016-2159-7.
The authors declare that they have no competing interests. This study is supported by the grant for the Clinical Research of Tokyo Metropolitan Hospital and Taiho Pharmaceutical Inc. who analyzed the thymidine synthase, thymidine phosphorylase, orotate phosphoribosyltransferase, and dihydropyrimidine dehydrogenase using RT-PCR.
The online version of the original article can be found under doi:10.1186/s12885-016-2159-7.
About this article
Cite this article
Okuma, Y., Hosomi, Y., Miyamoto, S. et al. Erratum to: Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma. BMC Cancer 16, 272 (2016). https://doi.org/10.1186/s12885-016-2309-y